EpistemisICS/LABA, LAMA/LABA and Triple Therapy Associations (LAMA/LABA/ICS)
Combined therapies in a single device optimize therapeutic adherence, ensure the simultaneous deposition of drugs in the same regions of the small airway and take advantage of reciprocal molecular synergies.
Mechanism
Reciprocal synergy mechanism
The combination of inhaled corticosteroids and β2 agonists is not merely additive, but is based on complementary genomic and intracellular interactions:
🧬 ICS powers LABACorticosteroids promote genomic transactivation that increases the expression of the β2-adrenergic receptor in the cell membrane. In addition, they effectively block the GRK kinases that mediate the desensitization of the β2 receptor, keeping the bronchodilator response intact over time.
⚡ LABA powers ICSStimulation of the β2 receptor activates PKA, which phosphorylates the glucocorticoid receptor (GR-α). This increases the affinity of the receptor for the exogenous corticosteroid and accelerates its nuclear translocation, increasing the anti-inflammatory effect with lower doses.
Physics and aerosol deposition
The effectiveness of an inhaled combination depends on the mean aerodynamic size of the particles (MMAD - *Mass Median Aerodynamic Diameter*):
- Extrafine particles (MMAD 1.0 - 1.5 µg): Present in formulations based on HFA propellants (such as beclomethasone/formoterol Modulite). They achieve a high intrapulmonary deposition (> 40%) and preferentially reach the small distal airway (bronchioles of caliber < 2 mm), a critical site of obstruction in severe asthma and COPD.
- Standard particles (MMAD 2.5 - 4.0 µg): They deposit mainly in the medium and large caliber airways, with greater secondary oropharyngeal clearance.
Key Combination Systems
| Association Type | Active Components | Commercial Name | Indication and Profile |
|---|---|---|---|
| ICS / LABA | Fluticasone propionate / Salmeterol | Seretide / Anoro | Maintenance of asthma (GINA 3-5) and COPD with eosinophilic phenotype. |
| ICS / LABA (SMART Regime) | Budesonide / Formoterol | Symbicort / Turbohaler | Dual use: Daily maintenance and immediate symptomatic relief in crisis. |
| LAMA / LABA | Umeclidinium / Vilanterol | Anoro Ellipta | Moderate-severe COPD (GOLD Group B or E with low eosinophilia). |
| LAMA / LABA | Tiotropium / Olodaterol | Spiolto Respimat | COPD. Soft mist system (SMI) with high lung deposit. |
| Triple Therapy | Fluticasone furoate / Umeclidinium / Vilanterol | Trelegy Ellipta | Single DPI device. Severe COPD and severe uncontrolled asthma. |
| Extrafine Triple Therapy | Beclomethasone dipropionate / Formoterol / Glycopyrronium | Trimbow | COPD and severe asthma. Extrafine size particles for small airways. |
SMART regimen (Single Maintenance and Reliever Therapy)
Using the Budesonide/Formoterol combination in a single inhaler for both daily maintenance and rescue symptom relief (replacing salbutamol) dramatically reduces the risk of severe asthma exacerbations compared to conventional treatment. This is because each rescue dose administered for mild symptoms automatically associates an extra dose of inhaled corticosteroid, treating inflammation early before it progresses to a severe outbreak.
Indicators and dose
Triple Therapy Dosing (DPI)
- Trelegy Ellipta (92 µg fluticasone furoate / 55 µg umeclidinium / 22 µg vilanterol): 1 inhalation per day at the same time in patients with severe COPD or poorly controlled asthma.
- Trimbow (87 µg beclomethasone / 5 µg formoterol / 9 µg glycopyrronium): 2 inhalations every 12 hours.
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Respiratory
- Cluster
- Combination Therapies in a Single Device